Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 33Lung Neoplasms 13Breast Neoplasms 12Colorectal Neoplasms 11Ovarian Neoplasms 10Recurrence 9Neoplasms 9Small Cell Lung Carcinoma 8Neoplasm Metastasis 8Head and Neck Neoplasms 8Urinary Bladder Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Lymphoma, Large B-Cell, Diffuse 7Prostatic Neoplasms 6Carcinoma, Hepatocellular 6Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 5Diabetes Mellitus, Insulin-Dependent, 12 5Carcinoma 5Multiple Myeloma 4Lymphoma, Follicular 4Cholangiocarcinoma 4Uterine Cervical Neoplasms 3Recurrent Squamous Cell Lung Carcinoma 3Oropharyngeal Neoplasms 3Mouth Neoplasms 3Mesothelioma 3Lymphoma, Non-Hodgkin 3Lymphoma 3Kidney Neoplasms 3

Interventions

Fluorouracil 3Radiotherapy 2Cisplatin 2Cetuximab 2rocakinogene sifuplasmid 1durvalumab 1VGX-3100 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Nivolumab 1Mitomycin 1Magnetic Resonance Spectroscopy 1MEDI0457 1Ipilimumab 1Immunoglobulin G 1Disulfides 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Anal Canal Carcinoma × durvalumab × Clear all
NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
41 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡